BioSyent Announces Approval of New Product
May 31 2023 - 4:42PM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is
pleased to announce that its subsidiary, BioSyent Pharma Inc., has
received regulatory approval from Health Canada for a new oncology
supportive care product. BioSyent Pharma Inc. signed an exclusive
Canadian Distribution Agreement for this product with a European
partner in December 2022.
“We are pleased to have received marketing
approval for this new product, bringing it one step closer to
launch in Canada,” said René Goehrum, President and CEO of
BioSyent. “We look forward to entering the oncology supportive care
therapeutic area with this new product which enhances our specialty
product portfolio and contributes to our ongoing
growth.”
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, specialty
and international business units.
As of the date of this press release, the
Company has 12,087,519 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein represent
our judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2024 to May 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2023 to May 2024